Bio-thera Solutions, Ltd. Class ASSE: 688177

"Bio-Thera Solutions, Ltd."Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report

Jul 1, 2026 · Issued by Bio-thera Solutions, Ltd. Class A via Shanghai Stock Exchange

Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Bio-thera Solutions, Ltd. Class A

Announcement on the Status of the EU GMP Inspection at the Yonghe FacilityJun 15
Announcement on Voluntary Disclosure of Obtaining Marketing Authorization Approval of BAT2206 (Ustekinumab Injection) by Singapore HSAJun 11
Announcement on Obtaining Drug Registration Certificate for ICHALIG®/XICHALIG® (Ustekinumab Injection)May 22
Bio-Thera Solutions' Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi(R) and Simponi Aria(R)May 19

All Bio-thera Solutions, Ltd. Class A news releases